Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Condition: Neuroendocrine CarcinomaInterventions: Biological: Recombinant Interferon Alfa-2b; Drug: Octreotide Acetate; Biological: BevacizumabSponsor: National Cancer Institute (NCI)Active, not recruiting - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials